Mumbai, June 30, 2017: Pharma Major Glenmark Pharmaceuticals today said that the company has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets-5 mg and 10 mg, Solifenacin Succinate tablets are used for treatment of overactive bladder, company said in a filing with BSE. The company’s products are the generic version of Vesicare tablets, 5 mg and 10 mg of Astellas Pharma US Inc. According to IMS Health April 2017 sales data, the market for Vesicare tablets-5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion. Glenmark’s current portfolio consists of 117 products authorised for distribution in the US marketplace, the company said, adding that it has 68 Abbreviated New Drug Applications (ANDA) pending with the USFDA
United News of India
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…